Obesity
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
  • Obesity Home
    • Products
      Obesity Treatments
    • Professional Resources
      Product Resources Library
  • Sample Requests
    • Disease Education
      Obesity: A Chronic Disease
    • Treatment Guidelines
      AACE Obesity Guidelines
    • Additional Resources
      Organizations & Conferences
    • Product Education
      Product Education Library
    • Disease Education
      Disease Education Library
    • Prescription Savings & Coverage
      Savings Cards Coverage Support
    • Support Programs
      Weight-Loss Support
  • Sign In
    Create Account
    • Account Settings
    • Sign Out
    Other Therapy Areas
    Medical Information
    Non-US Health Care Professionals
Wegovy® (semaglutide) injection 2.4 mg logo
Important Safety Information | Patient Site
Prescribing Information
    • The Impact of Obesity
    • How Weight Loss Can Help
    • Causes of Obesity
    • How Wegovy® Works
    • The Legacy of Semaglutide
    • STEP 1 Results
    • STEP 5 Results
    • STEP 4 Results
    • Cardiometabolic End Points
    • Common Adverse Events
    • Semaglutide Cardiovascular Safety Data
    • The Wegovy® Pen
    • Prescribing Wegovy®
    • Dose-Escalation Schedule
    • Navigating Coverage Eligibility
    • Co-pay Cards
    • For Pharmacists
    • WeGoTogether®
    • Frequently Asked Questions
    • Adolescent Indication Announcement
Wegovy® (semaglutide) injection 2.4 mg logo

For chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with a BMI ≥30 kg/m2 (obesity), or ≥27 kg/m2 (overweight) in the presence of a weight-related comorbidity, and for pediatric patients aged 12 years and older with an initial BMI at ≥95th percentile standardized for age and sex (obesity). Click for Limitations of Use.

Prescribing Information
Important Safety Information | Patient Site

We appreciate your interest in Wegovy®. To help answer patient questions about supply, click here.

Click here for important news about chronic weight management for your appropriate patients aged 12-17 with obesity.

Dosing & Administration

The Wegovy® Pen

Get to know the Wegovy® pen

The only GLP-1 RA for chronic weight management with once-weekly dosing

Wegovy® pens
Wegovy® pens

One and done
Single-use pen that patients dispose of after one use1

No dose dialing
Patients administer a preset dose for accurate dose delivery1

Autoinjector with an integrated needle
Patients will not need to see or handle a needle1

Dose-escalation schedule: Start your patients at the 0.25 mg once-weekly dose and follow the dose-escalation schedule. See the Wegovy® Prescribing Information for details1

  • If patients do not tolerate a dose during dose escalation, consider delaying dose escalation for 4 weeks
  • If patients do not tolerate the maintenance 2.4 mg once-weekly dose, the dose can be temporarily decreased to 1.7 mg once weekly, for a maximum of 4 weeks. After 4 weeks, increase Wegovy® to the maintenance 2.4 mg dose once weekly. Discontinue Wegovy® if the patient cannot tolerate the 2.4 mg dose
  • In patients with type 2 diabetes, monitor blood glucose prior to starting Wegovy® and during Wegovy® treatment


Wegovy® Pen Video
(1:47)

Review the complete Instructions for Use

Learn how to properly use the Wegovy® pen

Watch this short video to understand how to help train your patients to administer Wegovy®

Wegovy® Pen Video
(1:47)

Review the complete Instructions for Use

Administration Instructions1

10 seconds

The injection will take ~10 seconds, during which patients will hear 2 clicks. Direct them to press the pen firmly for the entire injection and not to remove the pen until the yellow bar has stopped moving.1

Injection pen icon

If they have problems injecting, change to a more firm injection site, such as upper leg or upper arm, or consider standing up while injecting into the lower stomach.1

Injection pen leaking icon

If medicine appears on the skin or leaks during injection; during the next injection, instruct patients to keep applying pressure until the yellow bar has stopped moving.1

Learn how to prescribe once-weekly Wegovy®

Get the prescribing table

Learn about Wegovy® straight from your phone

Phone

Interested in this optional program?
Text CHANGE to 54178 to join

This is an optional program intended for healthcare professionals. For more information about the informational program, the type of data involved, along with key resources, please see the informational program terms of use, found here.

Message and data rates may apply. Check with your service provider.

Wegovy® Dosing and Prescribing Guide
PDF
Share
A link has been copied to your clipboard.

Paste it into your email or chat app to share

Close
Wegovy® Dosing and Prescribing Guide
Learn about Wegovy® pen administration and dosing, prescribing, and storing Wegovy®. Get details on benefits verification and our WeGoTogether® support program.
Download
Add to order
Prescribing Information | Important Safety Information

Important Safety Information for Wegovy® (semaglutide) injection 2.4 mg

WARNING: RISK OF THYROID C-CELL TUMORS

  • In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy® causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined
  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy® and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy®

Indications and Usage

Wegovy® (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in:

  • adults with an initial body mass index (BMI) of ≥30 kg/m2 (obesity) or ≥27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) 
  • pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity)

Limitations of Use

  • Wegovy® contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist
  • The safety and effectiveness of Wegovy® in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established
  • Wegovy® has not been studied in patients with a history of pancreatitis

Important Safety Information

Contraindications

  • Wegovy® is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy®. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with Wegovy®

Warnings and Precautions

  • Risk of Thyroid C-Cell Tumors: Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging
  • Acute Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy® in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy® promptly, and if acute pancreatitis is confirmed, do not restart
  • Acute Gallbladder Disease: Treatment with Wegovy® was associated with an increased occurrence of cholelithiasis and cholecystitis. The incidence of cholelithiasis and cholecystitis was higher in Wegovy® pediatric patients aged 12 years and older than in Wegovy® adults. In clinical trials in adult patients, cholelithiasis was reported by 1.6% of Wegovy® patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy® patients and 0.2% of placebo patients. In a clinical trial in pediatric patients aged 12 years and older, cholelithiasis was reported by 3.8% of Wegovy® patients and 0% placebo patients. Cholecystitis was reported by 0.8% of Wegovy® pediatric patients and 0% placebo patients. Substantial or rapid weight loss can increase the risk of cholelithiasis; however, the incidence of acute gallbladder disease was greater in Wegovy® patients than in placebo patients, even after accounting for the degree of weight loss. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated
  • Hypoglycemia: Wegovy® lowers blood glucose and can cause hypoglycemia. In a trial of adult patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy® patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy® with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes
  • Acute Kidney Injury: There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy® in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion
  • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with Wegovy®. If hypersensitivity reactions occur, discontinue use of Wegovy®, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist
  • Diabetic Retinopathy Complications in Patients with Type 2 Diabetes: In a trial of adult patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy® patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy
  • Heart Rate Increase: Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy® adult patients compared to placebo in clinical trials. More Wegovy® adult patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). In a clinical trial in pediatric patients aged 12 years and older with normal baseline heart rate, more patients treated with Wegovy® compared to placebo had maximum changes in heart rate of 20 bpm or more (54% versus 39%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy®
  • Suicidal Behavior and Ideation: Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy® in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation

Adverse Reactions

  • Most common adverse reactions (incidence ≥5%) are: nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distention, eructation, hypoglycemia in patients with type 2 diabetes, flatulence, gastroenteritis, gastroesophageal reflux disease, and nasopharyngitis

Drug Interactions

  • The addition of Wegovy® in patients treated with insulin has not been evaluated. When initiating Wegovy®, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia
  • Wegovy® causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy®

Use in Specific Populations

  • Pregnancy: May cause fetal harm. When pregnancy is recognized, discontinue Wegovy®. Discontinue Wegovy® in patients at least 2 months before a planned pregnancy
  • Pediatric: Adverse reactions with Wegovy® in pediatric patients aged 12 years and older were similar to those reported in adults. Pediatric patients ≥12 years of age treated with Wegovy® had greater incidences of cholelithiasis, cholecystitis, hypotension, rash, and urticaria compared to adults treated with Wegovy®

Please click here for Prescribing Information, including Boxed Warning.

Reference

1. Wegovy® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.; 2022.

Obesity
Other Therapy Areas
Explore diabetes
Explore obesity
Explore rare bleeding disorders
Explore growth-related disorders
Explore hormone replacement therapy
  • Obesity Home
  • Product Information
    Products
    • Obesity Treatments
    Professional Resources
    • Product Resources Library
  • Sample Requests
  • Professional Education
    Disease Education
    • Obesity: A Chronic Disease
    Treatment Guidelines
    • AACE Obesity Guidelines
    Additional Resources
    • Organizations & Conferences
  • Patient Support
    Product Education
    • Product Education Library
    Disease Education
    • Disease Education Library
    Prescription Savings & Coverage
    • Savings Cards
      Coverage Support
    Support Programs
    • Weight-Loss Support

novoMEDLINK™ is a trademark of Novo Nordisk A/S.

Wegovy® and WeGoTogether® are registered trademarks of Novo Nordisk A/S.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.

This website is intended for US Health Care Professionals.

Legal Notice | Privacy Policy | Cookie Policy | Contact Us |
novonordisk-us.com    
© 2023 US23HCP00008 March 2023

Quick links

Request medication samples

Obesity treatment guidelines

Patient savings card offer

Patient support program